Abstracts tagged "clinical trials"

Abstract Number: 1827 • 2017 ACR/ARHP Annual Meeting
Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Data from a Phase 3 Trial
Pierre-Dominique Ghislain¹, Curdin Conrad², Yves Dutronc³, Carsten Henneges³, David Sandoval Calderon³, Myriam Vincent³, Liesbet Ghys³, Jolien de Gruijter³ and Peter C M van de Kerkhof⁴, ¹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³Eli Lilly and Company, Indianapolis, IN, ⁴Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: Nails are frequently involved in psoriasis and represent one of the most difficult to treat manifestations of the disease. This study evaluated the comparative…
Abstract Number: 1839 • 2017 ACR/ARHP Annual Meeting
Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials
Michal Abrahamowicz¹, John M. Esdaile², Rosalind Ramsey-Goldman³, Lee S. Simon⁴, Vibeke Strand⁵ and Peter E. Lipsky⁶, ¹Departmernt of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³FSM, Northwestern University, Chicago, IL, ⁴SDG LLC Consulting, West Newton, MA, ⁵Stanford University, Palo Alto, CA, ⁶AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Randomized controlled trials (RCTs) of new SLE treatments are hampered by the lack of effective outcome measures that are responsive to change and clinically…
Abstract Number: 318 • 2017 ACR/ARHP Annual Meeting
A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
Kenneth Saag¹, Jeffrey Petersen², Maria Luisa Brandi³, Andrew Karaplis⁴, Mattias Lorentzon⁵, Thierry Thomas⁶, Judy Maddox², Michelle Fan², Paul D. Meisner⁷ and Andreas Grauer², ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³University of Florence, Florence, Italy, ⁴McGill University, Montreal, QC, Canada, ⁵University of Gothenburg and Sahlgrenska University Hospital, Mölndal, Sweden, ⁶CHU de Saint-Étienne, Saint-Étienne, France, ⁷UCB Pharma, Brussels, Belgium
Background/Purpose: The bone forming agent romosozumab (Romo) was previously shown to reduce vertebral and clinical fractures in postmenopausal women with osteoporosis. Here we report the…
Abstract Number: 1886 • 2017 ACR/ARHP Annual Meeting
Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
E Michael Lewiecki¹, Rajani V Dinavahi², Marise Lazaretti-Castro³, Peter R Ebeling⁴, J Adachi⁵, Akimitsu Miyauchi⁶, Evelien Gielen⁷, Cassandra E Milmont², Cesar Libanati⁸ and Andreas Grauer², ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of São Paulo, São Paulo, Brazil, ⁴Monash University, Melbourne, Australia, ⁵McMaster University, Hamilton, ON, Canada, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷University Hospitals Leuven, Leuven, Belgium, ⁸UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is a monoclonal antibody that binds sclerostin with a dual effect, increasing bone formation and decreasing bone resorption. In the primary analysis…
Abstract Number: 437 • 2017 ACR/ARHP Annual Meeting
Recruitment of RA Trials in the Modern Era: Are United States-Based Trials Still Feasible?
Carla Maldini^1,2, Alfred Mahr³, David T. Felson^4,5 and Michael P. LaValley⁶, ¹Internal Medicine, Hospital Saint-Louis, Paris, France, ²Rheumatology, Hospital Córdoba, Cordoba, Argentina, ³Internal Medicine, University Hospital Saint-Louis, Paris, France, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ⁶Biostatistics, Boston University School of Public Health, Boston, MA
Background/Purpose: Timely recruitment of patients into interventional trials is necessary for their successful completion. The aim of this study was to evaluate recruitment rates of…
Abstract Number: 1904 • 2017 ACR/ARHP Annual Meeting
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib (ABT-494), a Selective JAK-1 Inhibitor, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Dmards
Gerd R. Burmester¹, Joel Kremer², Filip van Den Bosch³, Yihan Li⁴, Yijie Zhou⁴, Ahmed A. Othman⁵, Aileen L. Pangan⁴ and Heidi S. Camp⁵, ¹Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Albany Medical College, Albany, NY, ³Rheumatology, Ghent University Hospital, Gent, Belgium, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA) is an oral, selective JAK-1 inhibitor in development for the treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA) and…
Abstract Number: 509 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study
Mark C. Genovese¹, Joel Kremer², Sheng Zhong³ and Alan Friedman³, ¹Stanford University Medical Center, Palo Alto, CA, ²Albany Medical College, Albany, NY, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Upadacitinib (UPA, ABT-494) is a selective, oral JAK-1 inhibitor studied in two phase 2 randomized controlled trials (RCTs) in patients (pts) with rheumatoid arthritis…
Abstract Number: 1909 • 2017 ACR/ARHP Annual Meeting
Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study
Mark C. Genovese¹, Arthur Kavanaugh², Kevin Winthrop³, Maria Greenwald⁴, Lucia Ponce⁵, Favio Enriquez Sosa⁶, Mykola Stanislavchuk⁷, Minodora Mazur⁸, Alberto Spindler⁹, Regina Cseuz¹⁰, Natalya Nikulenkova¹¹, Maria Glowacka-Kulesz¹², Istvan Szombati¹³, Anna Dudek¹⁴, Neelufar Mozaffarian¹⁵, Joy Greer¹⁵, Xiao Ding¹⁵, Pille Harrison¹⁶, Annegret Van der Aa¹⁶, René Westhovens¹⁷ and Rieke Alten¹⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Medicine, University of California, San Diego, La Jolla, CA, ³Oregon Health Sciences University, Portland, OR, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Consulta Privada Dra. Lucia Ponce, Temuco, Chile, ⁶Clinstile SA de CV, Col., Mexico City, Mexico, ⁷Vinnitsa Regional Clinical Hospital, Vinnitsa, Ukraine, ⁸IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, ⁹Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ¹⁰Revita Reumatologiai Rendelo, Budapest, Hungary, ¹¹Vladimir Reg Clin Hosp, Vladimir, Russian Federation, ¹²Silesiana Centrum Medyczne, Wroclawska, Poland, ¹³QUALICLINIC Kft., Budapest, Hungary, ¹⁴Centrum Medyczne AMED Warszawa Targówek, Warszawa, Poland, ¹⁵Gilead Sciences, Inc, Foster City, CA, ¹⁶Galapagos NV, Mechelen, Belgium, ¹⁷KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ¹⁸Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) currently in Phase 3 development for the treatment of rheumatoid arthritis (RA).…
Abstract Number: 535 • 2017 ACR/ARHP Annual Meeting
Effect of a Step-up or Step-Down in Tofacitinib Dose on Efficacy and Safety in Long-Term Extension Studies
Ruediger Mueller¹, Hendrik Schulze-Koops², Daniel E Furst³, Stanley B Cohen⁴, Kenneth Kwok⁵, Anna Maniccia⁵, Lisy Wang⁶, Ermeg Akylbekova⁷ and Johannes von Kempis¹, ¹Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Klinikum der Universität München, Munich, Germany, ³UCLA, Los Angeles, CA, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT, ⁷QuintilesIMS, Durham, NC
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Efficacy and safety of tofacitinib 5 and 10 mg BID have been…
Abstract Number: 2074 • 2017 ACR/ARHP Annual Meeting
A Series of Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Studies to Evaluate the Efficacy, Safety, and Dose-Response Relationship of Orally Administered URC102, a Novel URAT1 Inhibitor, in Korean Patients with Gout
Jae-Bum Jun¹, Howard Lee², Chang-Hee Suh³, Chang Keun Lee⁴, Dong Wook Kim⁵, Jung-Yoon Choe⁶, Sang-Heon Lee⁷, Sang-Hyon Kim⁸, Seung-Jae Hong⁹, So-Young Bang¹⁰, Sung Jae Choi¹¹, Yong-Beom Park¹², Makoto Onohara¹³, Jeongeun Choi¹⁴, Jung Soo Song¹⁵ and Won Park¹⁶, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of (South), ³Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Inje University College of Medicine, Busan, Korea, Republic of (South), ⁶Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ⁷Division of Rheumatology, Department of Internal Medicine,, Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁸Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea, Daegu, Korea, Republic of (South), ⁹Department of Rheumatology, Kyung Hee University Medical Center, Seoul, Korea, Republic of (South), ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ¹¹Internal Medicine, Korea University Medical Center, Seoul, Korea, Republic of (South), ¹²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ¹³Science and Strategy, Translational Clinical Research, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan, ¹⁴JW Pharmaceutical Corporation, Seoul, Korea, Republic of (South), ¹⁵Rheumatology, Chung-Ang University College of Medicine, Seoul, Korea, Republic of (South), ¹⁶Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South)
Background/Purpose: URC102 is a novel URAT1 inhibitor under clinical development for the treatment of hyperuricemia with gout. A series of double-blind, placebo-controlled, randomized, multicenter, phase…
Abstract Number: 725 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Anabasum (JBT-101) is a selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses and limits fibrosis in animal models of…
Abstract Number: 2092 • 2017 ACR/ARHP Annual Meeting
Pilot Clinical Study of a Novel Unobtrusive Carpal Tunnel Tissue Manipulation Device in Reducing Symptoms of Carpal Tunnel Syndrome
Pauline Luong^1,2, Frank King³, Zong-Ming Li^2,4, Matt Dickason⁵, Matthew Diamond⁶ and Jae Son^1,2, ¹Pressure Profile Systems, Los Angeles, CA, ²Sohn Inc, Los Angeles, CA, ³Mission Pain and Spine Institute, Mission Viejo, CA, ⁴Biomedical Engineering, Orthopaedic Surgery, and Physical Medicine & Rehabilitatio, Cleveland Clinic, Cleveland, OH, ⁵Renaissance Associates, Newport Beach, CA, ⁶Rusk Institute of Rehabilitation Medicine, NYU School of Medicine, San Francisco, CA
Background/Purpose: Carpal tunnel syndrome (CTS) is the most common peripheral entrapment neuropathy and has been associated with systemic conditions such as rheumatoid arthritis, hypothyroidism, and…
Abstract Number: 726 • 2017 ACR/ARHP Annual Meeting
Performance of the American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the Scleroderma Lung Study-I
Dinesh Khanna¹, Donald P. Tashkin², Holly Wilhalme² and Chi-hong Tseng³, ¹University of Michigan, Ann Arbor, MI, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The CRISS has been proposed as a composite outcome measure for trials in systemic sclerosis1. CRISS is a 2-step process that assigns a probability…
Abstract Number: 2156 • 2017 ACR/ARHP Annual Meeting
Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist
Victoria P Werth¹, Emily Hejazi², Sandra M. Pena³, Jessica S. Haber⁴, Joyce Okawa³, Rui Feng⁵, Kirubel Gabre², Josef Concha², Scott Constantine⁶ and Barbara White⁶, ¹University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁵Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁶Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: There are limited treatment options and no published double-blind randomized placebo-controlled trials for the treatment of skin manifestations of dermatomyositis (DM). There is no…
Abstract Number: 738 • 2017 ACR/ARHP Annual Meeting
Prospective Validation of the Systemic Sclerosis Skin Symptoms Patient-Reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Ada Man¹, Nancy Dgetluck² and Barbara White³, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²Biostatistics, Corbus Pharmaceuticals, Norwood, MA, ³Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Skin thickening is the defining manifestation of dcSSc. A dcSSc patient’s assessment of their skin involvement can provide information about how that patient feels…

« Previous Page
1
…
4
5
6
7
8
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].